[{"data":1,"prerenderedAt":287},["ShallowReactive",2],{"drug-cefuroxime":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":44,"contraindications":143,"warnings":153,"renal":154,"monitoring":162,"interactions":163,"review":164,"examples":167,"atc":190,"iran":192,"links":232,"populations":247,"usApproval":282},"cefuroxime",1,{"fa":7,"en":8},"سفوروکسیم","Cefuroxime axetil","anti-infectives",{"fa":11,"en":12},"سفالوسپورین نسل دوم","Second-generation cephalosporin",[14],{"name":15,"market":16},"Ceftin","US",[18,19,20],"cefuroxim","زینات","zinnat",[22,36],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"susp-125-5","suspension","oral","125 mg \u002F 5 mL",{"amount":28,"unit":29,"perVolumeMl":30},125,"mg",5,[16],[33],{"source":34,"section":35},"fda-cefuroxime-susp","How Supplied",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"susp-250-5","250 mg \u002F 5 mL",{"amount":40,"unit":29,"perVolumeMl":30},250,[16],[43],{"source":34,"section":35},[45,79,102,123],{"id":46,"disease":47,"label":48,"population":51,"type":58,"unit":29,"dose":59,"refs":62,"limits":65,"durationDays":69,"notes":71},"pharyngitis","streptococcal-pharyngitis",{"fa":49,"en":50},"فارنژیت\u002Fتونسیلیت — ۲۰ mg\u002Fkg\u002Fday دو بار در روز","Pharyngitis\u002Ftonsillitis — 20 mg\u002Fkg\u002Fday twice daily",{"minAge":52,"maxAge":55},{"value":53,"unit":54},3,"month",{"value":56,"unit":57},13,"year","weightBased",{"perKgPerDay":60,"dividedDoses":61},20,2,[63],{"source":34,"section":64},"Dosage and Administration, Table 4",{"maxPerDay":66,"refs":67},500,[68],{"source":34,"section":64},{"min":70,"max":70},10,[72],{"text":73,"refs":76},{"fa":74,"en":75},"با غذا مصرف شود. قرص و سوسپانسیون معادل زیستی نیستند و میلی‌گرم به میلی‌گرم جایگزین نمی‌شوند.","Must be given with food. Tablets and suspension are not bioequivalent and not substitutable mg-for-mg.",[77],{"source":34,"section":78},"Dosage and Administration",{"id":80,"disease":81,"label":82,"population":85,"type":58,"unit":29,"dose":88,"refs":90,"limits":92,"durationDays":96,"notes":97},"aom","acute-otitis-media",{"fa":83,"en":84},"اوتیت مدیای حاد — ۳۰ mg\u002Fkg\u002Fday دو بار در روز","Acute otitis media — 30 mg\u002Fkg\u002Fday twice daily",{"minAge":86,"maxAge":87},{"value":53,"unit":54},{"value":56,"unit":57},{"perKgPerDay":89,"dividedDoses":61},30,[91],{"source":34,"section":64},{"maxPerDay":93,"refs":94},1000,[95],{"source":34,"section":64},{"min":70,"max":70},[98],{"text":99,"refs":100},{"fa":74,"en":75},[101],{"source":34,"section":78},{"id":103,"disease":104,"label":105,"population":108,"type":58,"unit":29,"dose":111,"refs":112,"limits":114,"durationDays":117,"notes":118},"sinusitis","acute-bacterial-sinusitis",{"fa":106,"en":107},"سینوزیت ماگزیلاری حاد — ۳۰ mg\u002Fkg\u002Fday","Acute maxillary sinusitis — 30 mg\u002Fkg\u002Fday",{"minAge":109,"maxAge":110},{"value":53,"unit":54},{"value":56,"unit":57},{"perKgPerDay":89,"dividedDoses":61},[113],{"source":34,"section":64},{"maxPerDay":93,"refs":115},[116],{"source":34,"section":64},{"min":70,"max":70},[119],{"text":120,"refs":121},{"fa":74,"en":75},[122],{"source":34,"section":78},{"id":124,"disease":124,"label":125,"population":128,"type":58,"unit":29,"dose":131,"refs":132,"limits":134,"durationDays":137,"notes":138},"impetigo",{"fa":126,"en":127},"زردزخم — ۳۰ mg\u002Fkg\u002Fday","Impetigo — 30 mg\u002Fkg\u002Fday",{"minAge":129,"maxAge":130},{"value":53,"unit":54},{"value":56,"unit":57},{"perKgPerDay":89,"dividedDoses":61},[133],{"source":34,"section":64},{"maxPerDay":93,"refs":135},[136],{"source":34,"section":64},{"min":70,"max":70},[139],{"text":140,"refs":141},{"fa":74,"en":75},[142],{"source":34,"section":78},[144],{"id":145,"severity":146,"text":147,"refs":150},"hypersensitivity","block",{"fa":148,"en":149},"آلرژی شناخته‌شده به سفالوسپورین‌ها.","Known allergy to the cephalosporin group.",[151],{"source":34,"section":152},"Contraindications",[],[155],{"egfrBelow":89,"severity":156,"text":157,"refs":160},"warn",{"fa":158,"en":159},"بی‌خطری در نارسایی کلیه ثابت نشده؛ نیمه‌عمر طولانی می‌شود.","Safety and efficacy in renal failure not established; half-life prolonged.",[161],{"source":34,"section":78},[],[],{"status":165,"reviewer":166,"date":166},"unverified",null,[168,173,178,182,187],{"regimen":46,"formulation":23,"input":169,"expect":170},{"ageYears":53,"weightKg":70},{"perDose":171,"mlPerDose":172},100,4,{"regimen":46,"formulation":37,"input":174,"expect":177},{"ageYears":175,"weightKg":176},12,40,{"perDay":66,"perDose":40},{"regimen":80,"formulation":37,"input":179,"expect":180},{"ageYears":53,"weightKg":70},{"perDose":181,"mlPerDose":53},150,{"regimen":103,"formulation":37,"input":183,"expect":185},{"ageYears":184,"weightKg":60},6,{"perDose":186},300,{"regimen":124,"formulation":37,"input":188,"expect":189},{"ageYears":175,"weightKg":176},{"perDay":93},[191],"J01DC02",{"status":193,"forms":194,"refs":227},"registered",[195,199,203,207,211,215,219,223],{"code":196,"en":197,"fa":198},"02029","CEFUROXIME AXETIL 125MG FC TAB","قرص روکش‌دار سفوروکسیم آکستیل ۱۲۵ میلی‌گرم",{"code":200,"en":201,"fa":202},"02030","CEFUROXIME AXETIL 125MG\u002F5ML FOR SUSP","سوسپانسیون سفوروکسیم آکستیل ۱۲۵ میلی‌گرم \u002F ۵ میلی‌لیتر",{"code":204,"en":205,"fa":206},"02031","CEFUROXIME AXETIL 250MG FC TAB","قرص روکش‌دار سفوروکسیم آکستیل ۲۵۰ میلی‌گرم",{"code":208,"en":209,"fa":210},"02032","CEFUROXIME AXETIL 500MG FC TAB","قرص روکش‌دار سفوروکسیم آکستیل ۵۰۰ میلی‌گرم",{"code":212,"en":213,"fa":214},"02420","CEFUROXIME AXETILE 250MG\u002F5ML FOR SUSP","سوسپانسیون سفوروکسیم آکستیل ۲۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر",{"code":216,"en":217,"fa":218},"02421","CEFUROXIME SODIUM 1.5 G VIAL","ویال سفوروکسیم سدیم ۱٫۵ گرم",{"code":220,"en":221,"fa":222},"02422","CEFUROXIME SODIUM 250MG VIAL","ویال سفوروکسیم سدیم ۲۵۰ میلی‌گرم",{"code":224,"en":225,"fa":226},"02423","CEFUROXIME SODIUM 750MG VIAL","ویال سفوروکسیم سدیم ۷۵۰ میلی‌گرم",[228],{"source":229,"section":230,"url":231},"darooyab-generic","G-353\u002FCefuroxime","https:\u002F\u002Fwww.darooyab.ir\u002FG-353\u002FCefuroxime",[233,237,241,244],{"kind":234,"url":235,"label":236},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=065323","ANDA065323",{"kind":238,"url":239,"label":240},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=135e2dfc-eb47-4d04-a903-a081d36c267e","FDA Cefuroxime susp",{"kind":242,"url":243,"label":191},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DC02",{"kind":245,"url":231,"label":246},"darooyab","Cefuroxime",{"pregnancy":248,"lactation":257,"pediatric":265,"geriatric":273},{"level":249,"text":250,"quote":253,"refs":254},"caution",{"fa":251,"en":252},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Teratogenic Effects: Pregnancy Category B.",[255],{"source":34,"section":256},"Pregnancy",{"level":249,"text":258,"quote":261,"refs":262},{"fa":259,"en":260},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because cefuroxime is excreted in human milk, consideration should be given to discontinuing nursing temporarily during treatment with cefuroxime axetil.",[263],{"source":34,"section":264},"Nursing Mothers",{"level":249,"text":266,"quote":269,"refs":270},{"fa":267,"en":268},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults.",[271],{"source":34,"section":272},"Pediatric Use",{"level":274,"text":275,"quote":278,"refs":279},"ok",{"fa":276,"en":277},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects.",[280],{"source":34,"section":281},"Geriatric Use",{"kind":283,"refs":284,"id":236},"ANDA",[285],{"source":34,"section":286},"SPL approval \u002F marketing category",1792444708500]